ZW49 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing ZW49, a new drug, to find the safest and most effective dose. It focuses on patients with advanced or metastatic HER2-positive cancers. The drug works by targeting and destroying cancer cells marked by the HER2 protein.
Who Is on the Research Team?
Joseph Woolery, PharmD, BCOP
Principal Investigator
Zymeworks BC Inc.
Are You a Good Fit for This Trial?
This trial is for patients with advanced HER2-positive cancers, including breast cancer and gastroesophageal adenocarcinoma (GEA), who have tried standard treatments without success or cannot tolerate them. Participants must have a confirmed diagnosis, measurable disease for certain cohorts, an ECOG performance status of 0 or 1 indicating they are fully active or restricted in physically strenuous activity but ambulatory, and adequate organ function.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
3+3 dose-escalation study design to evaluate the safety and tolerability of ZW49 and determine the MTD or RD
Expansion Cohorts
Selected expansion cohorts to further evaluate the safety and tolerability of ZW49 at the MTD or RD and assess preliminary anti-tumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ZW49
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zymeworks BC Inc.
Lead Sponsor
Zymeworks Inc.
Lead Sponsor